Mirum Pharmaceuticals
MIRM
104 hedge funds and large institutions have $650M invested in Mirum Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 47 increasing their positions, 25 reducing their positions, and 23 closing their positions.
206% more call options, than puts
Call options by funds: $422K | Put options by funds: $138K
88% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 25
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
2.76% less ownership
Funds ownership: 93.18% → 90.42% (-2.8%)
7% less funds holding
Funds holding: 112 → 104 (-8)
8% less capital invested
Capital invested by funds: $709M → $650M (-$58.9M)
30% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$15.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$15.2M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$13.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$9.55M |
| 5 |
BlackRock
New York
|
+$7.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$22.4M |
| 2 |
CCM
Cadian Capital Management
New York
|
-$19.5M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$14.6M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$11M |
| 5 |
O
OrbiMed
New York
|
-$11M |
MIRM Hedge Fund Activity: Q4 2022 in Review
104 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q4 2022, worth a combined $650M — down 8.3% from $709M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of MIRM and 16 opened new positions — a net loss of 7 holders — while 25 trimmed existing stakes and 47 added.
The largest buyer was Eventide Asset Management, adding an estimated $15.5M. The largest seller was Franklin Resources, cutting an estimated $22.4M.
- 104 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q4 2022, down from 112 in Q3 2022.
- Funds reported $650M of Mirum Pharmaceuticals stock for Q4 2022, down 8.3% quarter-over-quarter.
- 16 funds opened new Mirum Pharmaceuticals positions in Q4 2022 and 23 closed out, a net change of -7 holders.
- The largest Mirum Pharmaceuticals buyer in Q4 2022 was Eventide Asset Management, an estimated $15.5M added.
- The largest Mirum Pharmaceuticals seller in Q4 2022 was Franklin Resources, an estimated $22.4M sold.
Based on aggregated 13F filings for Q4 2022.